Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW192,900.00
+3,900.00 (+2.06%)
KR KOE Healthcare Medical - Pharmaceuticals
Address
351 Hyoryeong-ro 6643
Seoul, KR
Seoul, KR
CEO
Chun In Seok
Website
scd.co.kr
IPO
2001-09-11
ISIN KR7000250001
Description
Sam Chun Dang Pharm Co., Ltd. is a pharmaceutical company that develops and produces a wide variety of medications. Its product range features antibiotics, treatments for cardiovascular and respiratory conditions, drugs for the digestive system and ophthalmic use, as well as anti-inflammatory agents. The company was founded on December 29, 1943, and its main operations are based in Hwaseong-si, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW192,900.00
+3,900.00 (+2.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
307.8K
Beta
0.89
Float Shares
14.31M
Free Float %
61.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.84% | -14.12% | -29.87% | -46.71% | +56.55% | +39.26% | +144.44% | +428.73% | +463.74% | +3,581.08% | +20,412.05% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
192,900.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
29.74
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +9.5%+9.9% ★ Q1'26: +28.2% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +18.1%+207.0% ★ Q1'26: +1,034.0% (vs Q1'25)
-
FCF margin Medical - Pharmaceuticals: +29.9%-0.8% Q1'26: -35.2% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +4.8%+3.7% Q1'26: +8.4% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.0%+2.7% Q1'26: +5.4% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: -0.1%+1.9% Q1'26: +0.5% (vs Q1'25)
-
Debt / EBITDA Medical - Pharmaceuticals: -0.11×8.25× ★ Q1'26: 1.41× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
Dec 2032 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
132.06B
est: 132.70B (-0.5%)
|
147.37B
est: 146.10B (+0.9%)
|
160.59B
est: 154.00B (+4.3%)
|
159.96B
est: 141.80B (+12.8%)
|
186.60B
est: 186.40B (+0.1%)
|
166.86B
est: 188.90B (-11.7%)
|
167.27B
est: 170.40B (-1.8%)
|
177.34B
est: 181.30B (-2.2%)
|
192.67B
est: 195.40B (-1.4%)
|
210.92B
est: 195.40B (+7.9%)
|
154.00B
154.00B – 154.00B
-21.2% YoY
|
141.80B
141.80B – 141.80B
-7.9% YoY
|
186.40B
186.40B – 186.40B
+31.5% YoY
|
188.90B
188.90B – 188.90B
+1.3% YoY
|
170.40B
170.40B – 170.40B
-9.8% YoY
|
181.30B
181.30B – 181.30B
+6.4% YoY
|
195.40B
195.40B – 195.40B
+7.8% YoY
|
| EBITDA |
25.20B
est: 8.44B (+198.4%)
|
28.14B
est: 9.30B (+202.7%)
|
30.53B
est: 9.80B (+211.5%)
|
21.00B
est: 9.02B (+132.7%)
|
26.63B
est: 11.86B (+124.5%)
|
23.90B
est: 12.02B (+98.9%)
|
-10.91B
est: 10.84B (-200.6%)
|
19.36B
est: 11.54B (+67.8%)
|
6.55B
est: 12.43B (-47.3%)
|
20.45B
est: 10.09B (+102.6%)
|
7.95B
7.95B – 7.95B
-21.2% YoY
|
7.32B
7.32B – 7.32B
-7.9% YoY
|
9.63B
9.63B – 9.63B
+31.5% YoY
|
9.76B
9.76B – 9.76B
+1.3% YoY
|
8.80B
8.80B – 8.80B
-9.8% YoY
|
9.36B
9.36B – 9.36B
+6.4% YoY
|
10.09B
10.09B – 10.09B
+7.8% YoY
|
| EBIT |
20.98B
est: 2.87B (+631.3%)
|
22.78B
est: 3.16B (+621.2%)
|
24.28B
est: 3.33B (+629.2%)
|
14.69B
est: 3.07B (+379.3%)
|
20.13B
est: 4.03B (+399.7%)
|
17.22B
est: 4.08B (+321.7%)
|
-17.65B
est: 3.68B (-579.2%)
|
11.71B
est: 3.92B (+198.8%)
|
-1.88B
est: 4.22B (-144.5%)
|
11.42B
est: 1.59B (+616.0%)
|
1.26B
1.26B – 1.26B
-21.2% YoY
|
1.16B
1.16B – 1.16B
-7.9% YoY
|
1.52B
1.52B – 1.52B
+31.5% YoY
|
1.54B
1.54B – 1.54B
+1.3% YoY
|
1.39B
1.39B – 1.39B
-9.8% YoY
|
1.48B
1.48B – 1.48B
+6.4% YoY
|
1.59B
1.59B – 1.59B
+7.8% YoY
|
| Net Income |
11.63B
est: 20.35B (-42.8%)
|
8.71B
est: 22.79B (-61.8%)
|
12.51B
est: 25.46B (-50.8%)
|
8.75B
est: 9.16B (-4.4%)
|
10.45B
est: 17.01B (-38.6%)
|
-965.68M
est: 7.18B (-113.4%)
|
-16.56B
est: 10.36B (-259.8%)
|
5.84B
est: 18.32B (-68.1%)
|
-10.38B
est: 18.83B (-155.1%)
|
-10.92B
est: 19.19B (-156.9%)
|
25.94B
25.94B – 25.94B
+35.2% YoY
|
9.34B
9.34B – 9.34B
-64.0% YoY
|
17.33B
17.33B – 17.33B
+85.7% YoY
|
7.32B
7.32B – 7.32B
-57.8% YoY
|
10.56B
10.56B – 10.56B
+44.2% YoY
|
18.67B
18.67B – 18.67B
+76.9% YoY
|
19.19B
19.19B – 19.19B
+2.8% YoY
|
| SGA |
28.86B
est: 44.98B (-35.8%)
|
31.35B
est: 49.52B (-36.7%)
|
34.64B
est: 52.20B (-33.6%)
|
36.79B
est: 48.06B (-23.5%)
|
43.81B
est: 63.18B (-30.7%)
|
65.84B
est: 64.03B (+2.8%)
|
62.81B
est: 57.76B (+8.8%)
|
68.37B
est: 61.45B (+11.3%)
|
51.99B
est: 66.23B (-21.5%)
|
56.80B
est: 60.64B (-6.3%)
|
47.80B
47.80B – 47.80B
-21.2% YoY
|
44.01B
44.01B – 44.01B
-7.9% YoY
|
57.85B
57.85B – 57.85B
+31.5% YoY
|
58.63B
58.63B – 58.63B
+1.3% YoY
|
52.89B
52.89B – 52.89B
-9.8% YoY
|
56.27B
56.27B – 56.27B
+6.4% YoY
|
60.64B
60.64B – 60.64B
+7.8% YoY
|
| EPS |
570.03
est: 884.00 (-35.5%)
|
422.40
est: 990.00 (-57.3%)
|
585.10
est: 1,106.00 (-47.1%)
|
408.98
est: 398.00 (+2.8%)
|
488.26
est: 739.00 (-33.9%)
|
-44.57
est: 312.00 (-114.3%)
|
-750.19
est: 450.00 (-266.7%)
|
264.52
est: 796.00 (-66.8%)
|
-463.03
est: 818.00 (-156.6%)
|
-474.29
est: 818.00 (-158.0%)
|
1,106.00
1,106.00 – 1,106.00
+35.2% YoY
|
398.00
398.00 – 398.00
-64.0% YoY
|
739.00
739.00 – 739.00
+85.7% YoY
|
312.00
312.00 – 312.00
-57.8% YoY
|
450.00
450.00 – 450.00
+44.2% YoY
|
796.00
796.00 – 796.00
+76.9% YoY
|
818.00
818.00 – 818.00
+2.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-14 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-13 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-10 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-43.73B
OE per share TTM
-1,832.18
Owner's Yield
-0.74%
Maintenance CapEx ratio
135.21%
Maint CapEx / Avg PPE
46.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
22.20M
Shares Outstanding
23.26M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chun In Seok | Pres & Chief Executive Officer | — | male |
| Dae-In Yoon | Chairman and Chief Executive Officer | — | — |
| Dae-Wook Kim | Senior Managing Director | — | — |
| Gwang-Jin Lim | Managing Director | — | — |
| Hyung-Gyun Jeon | Managing Director | — | — |
| Tae-Eun Jang | Managing Director and Director | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000250.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
